| EXAMINATION | - BAETEN DOMINIQUE ET AL, "Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.", THE NEW ENGLAND JOURNAL OF MEDICINE 24 DEC 2015, (20151224), vol. 373, no. 26, ISSN 1533-4406, pages 2534 - 2548 | - |
| OPPOSITION | - "16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)", clinical trial NCT01649375, (20191030), URL: https://clinicaltrials.gov/ct2/show/NCT01649375, XP055660206 | - |
| OPPOSITION | - ANDREA CHIOATO, "Abstract 1822 - Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects Exposed to Secukinumab 150 Mg: Preliminary Study Results", Arthritis & Rheumatism, (20111000), vol. 63, no. 10, page S711, XP055661257 | - |
| OPPOSITION | - Anonymous, "16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)", ClinicalTrials.gov,, (20191030), URL: https://clinicaltrials.gov/ct2/show/NCT01649375, XP055660206 | - |
| OPPOSITION | - Anonymous, "AIN-457 for posterior uveitis", NHSC (National Horizon Scanning Centre), (20100500), pages 2 - 5, XP055661111 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00669916 - A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis", ClinicalTrials.gov Archive, (20081212), pages 1 - 4, URL: https://clinicaltrials.gov/ct2/history/NCT00669916?A=5&B=5&C=merged#StudyPageTop, XP055661161 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00669942- Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients AU - Anonymous", ClinicalTrials.gov Archive, (20100920), pages 1 - 4, URL: https://clinicaltrials.gov/ct2/history/NCT00669942?A=5&B=5&C=merged#StudyPageTop, XP055661196 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00805480 - Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis", (20090824), pages 1 - 4, URL: https://clinicaltrials.gov/ct2/history/NCT00805480?A=4&B=4&C=merged#StudyPageTop, XP055661148 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00809159 - Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis", ClinicalTrials.gov Archive, (20081216), pages 1 - 9, URL: http://clinicaltrials.gov/ct2/history/NCT00809159?V_5=View, XP055665223 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00809159 - Efficacy of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis", (20100622), pages 1 - 5, URL: https://clinicaltrials.gov/ct2/history/NCT00809159?A=5&B=5&C=merged#StudyPageTop, XP055661141 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00809614- Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis", ClinicalTrials.gov Archive, (20100429), pages 1 - 4, URL: https://clinicaltrials.gov/ct2/history/NCT00809614?A=5&B=5&C=merged#StudyPageTop, XP055661176 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00928512 - Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)", ClinicalTrials.gov Archive, (20100312), pages 1 - 5, URL: https://clinicaltrials.gov/ct2/history/NCT00928512?A=5&B=5&C=merged#StudyPageTop, XP055661202 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00928512 - Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)", ClinicalTrials.gov Archive,, (20100312), pages 1 - 5, URL: https://clinicaltrials.gov/ct2/history/NCT00928512?V_5=View, XP055661202 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT00995709", ClinicalTrials.gov Archive, (20101014), pages 1 - 6, URL: https://clinicaltrials.gov/ct2/history/NCT00995709?A=7&B=7&C=merged#StudyPageTop, XP055661216 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01032915 - Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis (ENDURE)", ClinicalTrials.gov Archive, (20101024), pages 1 - 8, URL: https://clinicaltrials.gov/ct2/history/NCT01032915?A=4&B=4&C=merged#StudyPageTop, XP055661210 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01071252- A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis", ClinicalTrials.gov Archive, (20100218), pages 1 - 4, URL: https://clinicaltrials.gov/ct2/history/NCT01071252?A=1&B=1&C=merged#StudyPageTop, XP055661154 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01090310 - Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Study (ENDURE)", ClinicalTrials.gov Archive, (20100927), pages 1 - 6, URL: https://clinicaltrials.gov/ct2/history/NCT01090310?A=2&B=2&C=merged#StudyPageTop, XP055661203 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01093846 - Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis (SHIELD)", ClinicalTrials.gov Archive, (20101013), pages 1 - 5, URL: https://clinicaltrials.gov/ct2/history/NCT01093846?A=2&B=2&C=merged#StudyPageTop, XP055661207 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01095250 - Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis (INSURE)", ClinicalTrials.gov Archive, pages 1 - 8, URL: https://clinicaltrials.gov/ct2/history/NCT01095250?A=6&B=6&C=merged#StudyPageTop, XP055661211 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01103024", ClinicalTrials.gov Archive, (20101015), pages 1 - 3, URL: https://clinicaltrials.gov/ct2/history/NCT01103024?A=2&B=2&C=merged#StudyPageTop, XP055661219 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01109940 - Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis", ClinicalTrials.gov Archive, (20100622), pages 1 - 4, URL: https://clinicaltrials.gov/ct2/history/NCT01109940?V_2=View, XP055661132 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01169844 -Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis", ClinicalTrials.gov Archive, (20100723), pages 1 - 4, URL: https://clinicaltrials.gov/ct2/history/NCT01169844?A=1&B=1&C=merged#StudyPageTop, XP055661183 | - |
| OPPOSITION | - anonymous, "History of Changes for Study: NCT01327664", ClinicalTrials.gov Archive, (20110331), pages 1 - 3, URL: https://clinicaltrials.gov/ct2/history/NCT01327664?V_1=View#StudyPageTop, XP055661282 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01358578", ClinicalTrials.gov Archive, (20110817), pages 1 - 13, URL: https://clinicaltrials.gov/ct2/history/NCT01358578?A=6&B=6&C=merged#StudyPageTop, XP055661265 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01359943", (20111018), URL: https://clinicaltrials.gov/ct2/history/NCT01359943?V_2=View#StudyPageTop, XP055660272 | - |
| OPPOSITION | - anonymous, "History of Changes for Study: NCT01365455", ClinicalTrials.gov Archive, (20111012), pages 1 - 10, URL: https://clinicaltrials.gov/ct2/history/NCT01365455?A=10&B=10&C=merged#StudyPageTop, XP055661269 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01392326", ClinicalTrials.gov Archive, (20110923), pages 1 - 7, URL: https://clinicaltrials.gov/ct2/history/NCT01392326?A=2&B=2&C=merged#StudyPageTop, XP055661272 | - |
| OPPOSITION | - anonymous, "History of Changes for Study: NCT01406938", ClinicalTrials.gov Archive, (10110815), pages 1 - 8, URL: https://clinicaltrials.gov/ct2/history/NCT01406938?A=2&B=2&C=merged#StudyPageTop, XP055661268 | - |
| OPPOSITION | - Anonymous, "History of Changes for Study: NCT01412944", ClinicalTrials.gov Archive, (20100808), pages 1 - 5, URL: https://clinicaltrials.gov/ct2/history/NCT01412944?A=1&B=1&C=merged#StudyPageTop, XP055661263 | - |
| OPPOSITION | - anonymous, "History of Changes for Study: NCT1350804", ClinicalTrials.gov Archive, (20110923), pages 1 - 4, URL: https://clinicaltrials.gov/ct2/history/NCT1350804?A=3&B=3&C=merged#StudyPageTop, XP055661280 | - |
| OPPOSITION | - anonymous, "History of Changes for Study: NCT1377012", ClinicalTrials.gov Archive, (20110928), pages 1 - 12, URL: https://clinicaltrials.gov/ct2/history/NCT1377012?A=4&B=4&C=merged#StudyPageTop, XP055661277 | - |
| OPPOSITION | - BAETEN et al., "The anti- IL -17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis, Abstract L7, Late-breaking abstracts: American College of Rheumatology 2010 annual scientific meeting", Arthritis & Rheumatism, (20101130), vol. 62, pages 3837 - 3845, XP002761818 | - |
| OPPOSITION | - BAETEN et al., "The anti- IL -17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis", Annals of Rheumatic Diseases, (20110000), vol. 70, no. 3, page 127 | - |
| OPPOSITION | - BAETEN et al., "The anti- IL 17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis", Annals of the Rheumatic Diseases, (20110500), vol. 70, no. 3 | - |
| OPPOSITION | - BAETEN et al., "The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis", Arthritis & Rheumatism, (20100000), vol. 62, no. 12, pages 3840 - 3841, XP055660219 | - |
| OPPOSITION | - BAETEN et al., "The anti- IL 17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis", Arthritis & Rheumatism, (20101130), vol. 62, no. 12, pages 3840 - 3841, XP055660219 | - |
| OPPOSITION | - BARALIAKOS et al., "Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging, Abstract 2486D", Arthritis & Rheumatism, (20111000), vol. 63, no. 10, page S972, XP002761826 | - |
| OPPOSITION | - BARALIAKOS X. et al., "Abstract 2486D - Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging", Arthritis & Rheumatism, (20110000), vol. 63, no. 10, page S972, XP009170121 | - |
| OPPOSITION | - "Cimzia® (certolizumab pegol)", FDA label, (201007), pages 1 - 25, XP055660231 | - |
| OPPOSITION | - C.M. SAMSON et al., "An Open-Label Proof-Of Concept Study to Assess the Efficacy of AIN457 in Patients With Noninfectious Uveitis", ARVO Annual Meeting Abstract, (20100400), URL: https://iovs.arvojournals.org/article.aspx?articleid=2371574, XP055661101 | - |
| OPPOSITION | - GENOVESE et al., "Abstract 401 - One Year Efficacy and Safety Results of a phase II Trial of Secukinumab in Patients with Rheumatoid Arthritis", Arthritis & Rheumatism, (20111000), vol. 63, no. 10, pages S149 - S150, XP055661237 | - |
| OPPOSITION | - GENOVESE et al., "Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment: results of a phase IIb study", Arthritis & Rheumatism, (20101130), vol. 62, no. 12, page 3842, XP055660239 | - |
| OPPOSITION | - GENOVESE et al., "Secukinumab (AIN457), a novel monoclonal antibody targeting IL -17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment: results of a phase Ilb study", Arthritis & Rheumatism, (20101130), vol. 62, no. 12, page 3842, XP055660239 | - |
| OPPOSITION | - GENOVESE et al., "Secukinumab (AIN457) showed a rapid decrease of disease activity in patients with active rheumatoid arthritis patients including those with high inflammatory burden", Annals of the Rheumatic Diseases, (20110500), vol. 70, no. 3 | - |
| OPPOSITION | - "History of Changes for Study: NCT01358175", clinical trial NCT01358175, (20170127), URL: https://clinicaltrials.gov/ct2/history/NCT01358175?V 2=View#StudyPageTop, XP055660258 | - |
| OPPOSITION | - "History of Changes for Study: NCT01359943", clinical trial NCT01359943, (20111018), URL: https://clinicaltrials.qov/ct2/historv/NCT01359943?V 2=View#StudyPageTop, XP055660272 | - |
| OPPOSITION | - INMAN et al., "Efficacy and safety of Golimumab in patients with ankylosing spondylitis", Arth & Rheum., (20080000), vol. 58, no. 11, pages 3402 - 3412, XP055665248 | - |
| OPPOSITION | - Mark Genovese; Patrick Durez Et Al, "Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment: results of a phase IIb study", Arthritis & Rheumatism, (20100000), vol. 62, no. 12, page 3842, XP055660239 | - |
| OPPOSITION | - MCINNES I. et al., "Abstract 779 - Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial", Arthritis & Rheumatism, (20111000), vol. 63, no. 10, page S306, XP055661240 | - |
| OPPOSITION | - NESS, "Surveying the Pipeline of Biologics to Treat Inflammatory Conditions", Pharmacy Times, (20110912), URL: https://www.pharmacytimes.com/publications/issue/2011/August2011/Surveying-the-Pipeline-of-Biologics-to-Treat-Inflammatory-Conditions-, XP055660252 | - |
| OPPOSITION | - Paul P. Tak, "AIN457 Shows a Good Safety Profile and Clinical Benefit in Patients with Active Rheumatoid Arthritis (RA) Despite Methotrexate Therapy: 16-Weeks Results From a Randomized Proof-of-Concept Trial", 2009 ACR/ARHP Annual Scientific Meeting, (20091020), URL: https://acr.confex.com/acr/2009/webprogram/Paper9270.html, XP055661096 | - |
| OPPOSITION | - Reuters, "Study: Drug Helps With Psoriasis Symptoms | Fox News", Press Release of Novartis, (20151026), URL: https://www.foxnews.com/health/study-drug-helps-with-psoriasis-symptoms, XP055660266 | - |
| OPPOSITION | - VAN DER HEIJDE et al., "Efficacy and safety of Infliximab in patients with ankylosing spondylitis", Arth & Rheum., (20050000), vol. 52, no. 2, pages 582 - 591, XP055665254 | - |
| OPPOSITION | - DAVIS et al., "Recombinant human tumour necrosis factor receptor (Etanercept) for treating ankylosing spondylitis", Arth & Rheum., (20030000), vol. 48, no. 11, pages 3230 - 3236, XP055665246 | |
| OPPOSITION | - Alan J. Kivitz, Ulf Wagner, Eva Dokoupilova, Jerzy Supronik, Ruvie Martin, Zsolt Talloczy, Hanno B. Richards, Brian Porter, "Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study", Rheumatology and Therapy, (20180000), vol. 5, no. 2, pages 447 - 462, XP055661296 | |
| OPPOSITION | - BAETEN et al., "Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis", New England Journal of Medicine, (20150000), vol. 373, no. 26, pages 2534 - 2548, XP055661305 | |
| OPPOSITION | - BAETEN et al., "Secukinumab, an lnterleukin-17A inhibitor in ankylosing spondylitis", New England Journal of Medicine, (20151224), vol. 373, pages 2534 - 2548, XP055661305 | |
| OPPOSITION | - HUEBER et al., "Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis", Science Translational Medicine, (20100000), vol. 2, no. 52, pages 1 - 9, XP009155660 | |
| OPPOSITION | - HUEBER et al., "Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis", Science Translational Medicine,, (20101006), vol. 2, no. 52 / Article No.: 52ra72, pages 1 - 9, XP009155660 | |
| OPPOSITION | - VAN DER HEIJDE et al., "Adalimumab effectiveness for the treatment of ankylosing spondylitis", Ann Rheum Dis., (20090000), vol. 68, pages 922 - 929, XP055665242 | |
| OPPOSITION | - PAVELKA et al., "Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3", Arthritis Research & Therapy, (20170000), vol. 19, no. 1, pages 1 - 10, XP055661289 | |
| OPPOSITION | - Janice M. Reichert, "Antibody-based therapeutics to watch in 2011", mAbs, (20110000), vol. 3, no. 1, pages 76 - 99, XP002675052 | |
| SEARCH | - BARALIAKOS XENOFON ET AL, "Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging", ARTHRITIS & RHEUMATISM; 75TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY/46TH ANNUAL SCIENTIFIC MEETIN; CHICAGO, IL, USA; NOVEMBER 04 -09, 2011, WILEY INTERSCIENCE, US, (20111101), vol. 63, no. 10, Suppl. S, ISSN 0004-3591, page S972, XP009170121 [IP] 1-16,18 * the whole document * | - |
| SEARCH | - Dominique Baeten et al, "L7 - The Anti-IL17A Monoclonal Antibody Secukinumab (AIN457) Showed Good Safety and Efficacy in the Treatment of Active Ankylosing Spondylitis.", (20101130), LATE-BREAKING ABSTRACTS: AMERICAN COLLEGE OF RHEUMATOLOGY 2010 ANNUAL SCIENTIFIC MEETING, URL: http://onlinelibrary.wiley.com/doi/10.1002/art.30132/pdf, (20160914), XP002761818 [IP] 1-16,18 * the whole document * | - |
| SEARCH | - ERIK LUBBERTS, "Th17 cytokines and arthritis", SEMINARS IN IMMUNOPATHOLOGY, SPRINGER, BERLIN, DE, (20100204), vol. 32, no. 1, ISSN 1863-2300, pages 43 - 53, XP019800827 [A] 1-16,18 * the whole document * | - |
| SEARCH | - McInnes, "Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.", (201010), Arthritis & Rheumatism, Volume 63,November 2011 Abstract Supplement, URL: http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=781&id=95525, (20160914), XP002761820 [I] 1-15,17,18 * the whole document * | - |
| SEARCH | - Novartis, "View of NCT00809159 on 2010_06_22", (20100622), ClinicalTrials.gov archive, URL: https://clinicaltrials.gov/archive/NCT00809159/2010_06_22, (20160907), XP002761819 [A] 1-16,18 * the whole document * | - |
| SEARCH | - Novartis, "View of NCT00809614 on 2010_04_29", (20100429), ClinicalTrials.gov archive, URL: https://clinicaltrials.gov/archive/NCT00809614/2010_04_29, (20160914), XP002761821 [A] 1-15,17,18 * the whole document * | - |
| SEARCH | - MARK GENOVESE ET AL, "Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment: Results of a phase IIb study", ARTHRITIS & RHEUMATISM; ABSTRACTS OF THE AMERICAN COLLEGE OF RHEUMATOLOGY & ASSOCIATION OF RHEUMATOLOGY HEALTH PROFESSIONALS, ANNUAL SCIENTIFIC MEETING, JOHN WILEY & SONS, INC, US; ATLANTA, GEORGIA, USA, vol. 62, no. Suppl. 10, doi:10.1002/ART.30166, ISSN 0004-3591, (20101001), (20101228), XP008147986 [A] 1-18 * the whole document * | |
